A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease
Public ClinicalTrials.gov record NCT00615199. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study To Investigate The Safety And Efficacy Of CP-690,550 In Subjects With Moderate To Severe Crohn's Disease.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease. The study hypothesis is that at least one of the dose levels to be tested will be more effective than placebo (inactive drug).
Study identification
- NCT ID
- NCT00615199
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 139 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2007
- Primary completion
- Sep 30, 2009
- Completion
- Sep 30, 2009
- Last update posted
- Jan 24, 2013
2008 – 2009
United States locations
- U.S. sites
- 39
- U.S. states
- 19
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | 35233 | — |
| Pfizer Investigational Site | Mobile | Alabama | 36617 | — |
| Pfizer Investigational Site | Boulder | Colorado | 80304 | — |
| Pfizer Investigational Site | Lakewood | Colorado | 80215 | — |
| Pfizer Investigational Site | Wheat Ridge | Colorado | 80033 | — |
| Pfizer Investigational Site | Washington D.C. | District of Columbia | 20006 | — |
| Pfizer Investigational Site | Boca Raton | Florida | 33428 | — |
| Pfizer Investigational Site | Boca Raton | Florida | 33442 | — |
| Pfizer Investigational Site | Boca Raton | Florida | 33486 | — |
| Pfizer Investigational Site | Boca Raton | Florida | 33496 | — |
| Pfizer Investigational Site | Gainesville | Florida | 32605 | — |
| Pfizer Investigational Site | Gainesville | Florida | 32607 | — |
| Pfizer Investigational Site | Jacksonville | Florida | 32207 | — |
| Pfizer Investigational Site | Jacksonville | Florida | 32256 | — |
| Pfizer Investigational Site | St. Petersburg | Florida | 33709 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60637 | — |
| Pfizer Investigational Site | Wichita | Kansas | 67208 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40202 | — |
| Pfizer Investigational Site | Chevy Chase | Maryland | 20815 | — |
| Pfizer Investigational Site | Towson | Maryland | 21204 | — |
| Pfizer Investigational Site | Troy | Michigan | 48098 | — |
| Pfizer Investigational Site | Rochester | Minnesota | 55905 | — |
| Pfizer Investigational Site | Mexico | Missouri | 65265 | — |
| Pfizer Investigational Site | Great Neck | New York | 11021 | — |
| Pfizer Investigational Site | Charlotte | North Carolina | 28209 | — |
| Pfizer Investigational Site | Charlotte | North Carolina | 28210 | — |
| Pfizer Investigational Site | Charlotte | North Carolina | 28211 | — |
| Pfizer Investigational Site | Salisbury | North Carolina | 28144 | — |
| Pfizer Investigational Site | Dayton | Ohio | 45415 | — |
| Pfizer Investigational Site | Duncansville | Pennsylvania | 16635 | — |
| Pfizer Investigational Site | Pittsburgh | Pennsylvania | 15243 | — |
| Pfizer Investigational Site | Upper Saint Clair | Pennsylvania | 15241 | — |
| Pfizer Investigational Site | Bristol | Tennessee | 37620 | — |
| Pfizer Investigational Site | Kingsport | Tennessee | 37660 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37205 | — |
| Pfizer Investigational Site | Dallas | Texas | 75235 | — |
| Pfizer Investigational Site | Dallas | Texas | 75390-8887 | — |
| Pfizer Investigational Site | Seattle | Washington | 98195 | — |
| Pfizer Investigational Site | Charleston | West Virginia | 25304 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00615199, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 24, 2013 · Synced Sep 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00615199 live on ClinicalTrials.gov.